1Ehnlnger G, Schuler U, Prokseh B, et al. Pharmacokinetics and metabolism of mitoxantrone: A review [J]. Clin Pharmacokinel, 1990,18(5} :365 - 380.
2Rizvi SA,Zwibel H, Fox EJ. Mitoxantrone for multiple sclerosis in clinical practice[J]. Neurology,2004,63(12 Suppl 6) :s25 - s27.
3Cabre P,Olindo S, Marignier R, et al. Efficacy of mioxantrone in neuromyelitis optica spectrum:Clinical and neuroradiological study [J]. J Neurol Neurosurg Psychiatry,2013,84(5) :511 - 516.
4Kroger N, Damon L, Zander AR, et al. Secondary acute leukemia following mitoxantrone - based high - dose chemotherapy for pri mary breast cancer patients [J]. Bone Marrow Transplant, 2003, 32(12) :1153-1157.
5Harrison E, Porter B:k nurse - led, patient - centred mitoxantrone service in neurology[J]. Br J Nurs,2004,13(17) :1021 - 1023.
8Dunn CJ ,Goa KI: Mitoxantrone: A review of its pharmacological properties and use in acute nonlymphoblaslic leukaemia[J]. Drugs Aging,1996,9(2):122 -147.
9Jamroz - Wisniewska A, Beltowski J, Stelmasiak Z, et al. Paraox onase 1 activity in multiple sclerosis patients during mitoxantro ne therapy[J]. Acta Neurol Scand,2013,127(6):e33- e36.
10Singhal BS, Geeta S, Hundalani SG, et al. Efficacy and safety of mitoxantrone,as an initial therapy,in multiple sclerosis: Experi ence in an Indian tertiary care setting[J]. Neurol India,2009,57 (4) :418 - 423.
